Did Exelixis use a 'trivial' modification to its cash cow to product hop past a patent cliff? These researchers think so

Exelixis CEO Michael Morrissey faces criticism from researchers including Mark Ratain, who allege zanzalintinib is a

Raccontata daendpoints.news